Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

3.24
+0.11003.51%
Post-market: 3.21-0.0300-0.93%19:30 EDT
Volume:480.79K
Turnover:1.56M
Market Cap:300.26M
PE:-8.39
High:3.29
Open:3.17
Low:3.16
Close:3.13
52wk High:10.40
52wk Low:2.26
Shares:92.67M
Float Shares:91.12M
Volume Ratio:0.87
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3863
EPS(LYR):-0.5438
ROE:-30.78%
ROA:-19.50%
PB:2.47
PE(LYR):-5.96

Loading ...

Anavex keeps EMA talks after withdrawing EU blarcamesine filing for early Alzheimer’s

Reuters
·
Mar 30

Anavex Life Sciences Corp - Continues Dialogue With European Medicines Agency on Oral Blarcamesine for Early Alzheimer's Disease

THOMSON REUTERS
·
Mar 30

Ema's Chmp: Application for Initial Marketing Authorisation of Blarcamesine Anavex Was Withdrawn.

THOMSON REUTERS
·
Mar 27

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 27

Top Midday Decliners

MT Newswires Live
·
Mar 26

Anavex withdraws marketing authorization application for blarcamesine in the EU

TIPRANKS
·
Mar 25

Anavex Life Sciences Corp - Withdraws EU Marketing Authorization Application for Blarcamesine

THOMSON REUTERS
·
Mar 25

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

GlobeNewswire
·
Mar 25

Anavex Life Sciences withdraws EU marketing authorization application for blarcamesine; EMA CHMP feedback drops chances of a positive opinion

Reuters
·
Mar 25

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 23

Anavex Life Sciences Presents New Data From Its Ad-004 Phase Iib/Iii Trial at Ad/Pd 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease

THOMSON REUTERS
·
Mar 23

Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment

Reuters
·
Mar 23

Anavex reports blarcamesine motor function rescue in new Parkinson’s disease model at AD/PD 2026

Reuters
·
Mar 17

What's Going On With Anavex Life Sciences Stock On Wednesday?

Benzinga_recent_news
·
Mar 05

Anavex Life Sciences CEO Christopher Missling to Present at Citizens Life Sciences Conference

Reuters
·
Mar 03

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

GlobeNewswire
·
Mar 03

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

GlobeNewswire
·
Feb 25

Anavex Life Sciences CEO Christopher U Missling to Present at TD Cowen Annual Health Care Conference

Reuters
·
Feb 25

Anavex Life Sciences Names Dr. Axel Paeger to Board of Directors

Reuters
·
Feb 23

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

GlobeNewswire
·
Feb 23